Contract research and manufacturing company Syngene International has had a fabulous run this year. Its stock price has risen over 40% since January amid robust growth and a positive outlook for the business. Syngene’s market capitalisation has reached INR33,000 crore, surpassing the INR32,600 crore market cap of its parent company Biocon. Since its listing in 2015, the Syngene stock has been rising steadily. Its market cap touched INR20,000
Related Posts
PharmEasy has skipped the growth pill for profitability. This may lead to side effects
Healthtech company PharmEasy seems to finally be able to hold its head above water. The unicorn, which has been struggling with slowing growth, debt burden, and steep valuation cuts by investors, had something to cheer about when it turned Ebitda (earnings before interest, taxes, depreciation and amortisation) profitable in April this year. For venture capital […]
us shark tank: Selling cut-price generics, Mark Cuban is shaking up US pharma. Can Indian drug makers benefit?
Getty Images Mark Cuban. Synopsis Most of the large Indian pharma companies earn a big chunk of their revenue by supplying drugs to the US market. Shark Tank attraction Cuban’s online pharmacy launched last year, which sources medicines directly from manufacturers, holds the promise of catalysing the US businesses of Indian generic drug makers. US-based […]
Dilip Jose: Manipal Health has set its sights on the top spot. Can it get there amid the intense competition?
Dilip Jose, Managing Director and CEO at Manipal Hospitals Synopsis Of late, Manipal Health has been focusing on getting bigger and improving operational efficiencies. With an aggressive and execution-oriented management and backing of marquee investors, it has expanded rapidly via the acquisitions route. However, with key rival Apollo Hospitals also increasing bed count across regions, […]